Detection and treatment of early stage prostate cancer. Seminar. USA, 1993/12.
The appropriateness of adopting a new screening policy depends on the burden of suffering from the disease, and on the effectiveness, potential harms and costs of screening.
Prostate cancer clearly satisfies the first requirement but the relationship among its benefits, harms and costs is uncertain due to lack of data.
Available screening tests (for example prostate specific antigen) can detect early stage disease but there is no evidence that clinical outcomes are improved by early detection.
The potential harms of screening 28 million men older than 50 years include unnecessary interventions for thousands of men without disease or with clinically insignificant cancer.
The billions of dollars required for this effort could displace resources away from health care services of proved benefit.
Mots-clés Pascal : Epithélioma, Prostate, Stade précoce, Etats Unis, Amérique du Nord, Amérique, Dépistage, Homme, Mâle, Appareil urinaire pathologie, Prostate pathologie, Appareil génital mâle pathologie, Tumeur maligne
Mots-clés Pascal anglais : Carcinoma, Prostate, Early stage, United States, North America, America, Medical screening, Human, Male, Urinary system disease, Prostate disease, Male genital diseases, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0217758
Code Inist : 002B14D02. Création : 09/06/1995.